Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04039217 · ClinicalTrials.gov registry record · Phase 4
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04039217 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT04039217, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how long it persists in different body compartments, including mucosal tissues, as it may be considered for PrEP or PEP regimens in the future.
Interventions
- DRUG Biktarvy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2020-08-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04039217
The ClinicalTrials.gov registry entry for NCT04039217 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biktarvy is the first listed.
NCT04039217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04039217 about?
NCT04039217 is a clinical study titled "Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM". The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how long it persists in different body compartments, including mucosal tissues, as it may be considered for PrEP or PEP regimens ...
What is the current status of trial NCT04039217?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2019-09-30. Estimated completion is 2020-08-28.
What interventions are being tested in trial NCT04039217?
The interventions under investigation include: Biktarvy (DRUG).
Who is sponsoring clinical trial NCT04039217?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.